Fusion Antibodies PLC (FAB) — Cash Flow Reinvestment Rate

Latest as of March 2022: 0.39x

Fusion Antibodies PLC (FAB) has a Cash Flow Reinvestment Rate of 0.39x as of March 2022, reinvesting GBX67.00K (capex GBX67.00K ) from operating cash flow of GBX174.00K. Explore reinvestment intensity of Fusion Antibodies PLC to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.39x

(Capex + Investments) / Operating CF

Total Reinvested

GBX67.00K

Capex + Investments

Operating Cash Flow

GBX174.00K

GBX

Capital Expenditures

GBX67.00K

GBX

Fusion Antibodies PLC Cash Flow Reinvestment Rate (2016–2018)

Historical reinvestment intensity for Fusion Antibodies PLC across 2 annual periods. Also explore FAB total asset value for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Fusion Antibodies PLC (2016–2018)

Year-by-year capital reinvestment analysis for Fusion Antibodies PLC. For live market cap and broader valuation context, see FAB stock market capitalisation.

Year	Reinvestment Rate	Total Reinvested (GBX)	Operating CF	Capex	YoY Change
2018	11.52x	GBX889.19K	GBX77.19K	GBX444.60K	▲ +11063.6%
2016	0.10x	GBX35.76K	GBX346.57K	GBX35.76K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow